Sanofi SA has received a second multi-million dollar contract from the US government’s biomedical advanced research and development authority (BARDA) for research into new medicinal products – this time for a product to treat acute radiation syndrome in the event of a public health emergency.
Alnylam Pharmaceutials Inc, the world’s leading developer of therapies based on RNA interference (RNAi) , has stopped development of revusiran, a treatment for a hereditary amyloidosis with cardiomyopathy, a condition caused by the abnormal accumulation of amyloid proteins in the body.
A collaborative research project between scientists at the University of Texas MD Anderson Cancer Center and Karus Therapeutics Ltd, a venture capital-backed company in the UK, has yielded a candidate drug inhibiting P13K, a target of growing interest to the pharmaceutical industry.
AstraZeneca Plc’s anti-platelet agent Brilinta (ticagrelor) has failed to show a significant benefit over Plavix in a Phase 3 study of patients with symptomatic peripheral artery disease (PAD) – the second trial failure this year for the drug.
A new combination therapy trial designed to test kinase and checkpoint inhibitors together to see whether they are effective in treating mesothelioma, non-small cell lung and pancreatic cancers, is expected to start late this year or early in 2017.
Bavarian Nordic A/S and Janssen Pharmaceutical are progressing their vaccine technology against the Ebola virus with plans to start a human study in a second-generation multivalent vaccine for Ebola and two other related viruses.
A study of patients with chronic obstructive pulmonary disease (COPD) who were treated with a new GlaxoSmithKline Plc medicine compared with the standard of care, has shown a benefit for the new medicine in everyday clinical practice.
The European Medicines Agency is recommending a tightening of its guideline on first-in-human clinical trials to provide better protections for volunteers and a new approach to evaluating protocols that cover a number of different study parts.
A review of patients who had experienced a stroke and were treated with an experimental stem cell therapy has shown the therapy to be safe and linked to improved neurological function. Data from a two-year follow-up of the patients were published in The Lancet on 20 August.
After years of investing in a product for stroke that failed, and then relaunching its portfolio around anaesthesia, Paion AG now has its sights firmly set on the commercialisation of its lead product, remimazolam, in the US.